SMi's 4th Annual 3D Cell Culture

SMi Group 19 - 20 February 2020, London, UK.
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

SMi's 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.

Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.

For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech's and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.

Featured speakers include

  • Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, MHRA
  • Veronique Barban, Expert Virology, Research and Nonclinical Safety Department, Sanofi Pasteur
  • Simone Stahl, Associate Principal Scientist, ADME Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca
  • Wendy Rowan, Scientific Director, Novel Human Genetics Research Unit, GSK
  • Jason Ekert, Head of Complex In Vitro Models, GSK
  • Samuel Jackson, Programme Manager, Disease Models Efficacy and Safety Pharmacology, NC3RS

Key topics include

  • Learn from leading pharma companies to benchmark against their applications of 3D technology
  • Explore case studies of 3D cell culture, high throughput screening, imaging and microphysiological systems in industry
  • Hear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models
  • Discuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research
  • Participate in a panel discussion on adopting new technologies for 3D models

For more information and to register, please visit:
http://www.3D-cellculture.com/wpnWL

Early-Bird Rates

  • Register by 29th November to save £200
  • Register by 29th December to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...